Načítá se...
Programmed cell death-ligand 1 assessment in urothelial carcinoma: prospect and limitation
Programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibition has revolutionized the treatment paradigm of urothelial carcinoma (UC). Several PD-L1 assays are conducted to formulate appropriate treatment decisions for PD-1/PD-L1 target therapy in UC. However, each assay has its o...
Uloženo v:
| Vydáno v: | J Pathol Transl Med |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
The Korean Society of Pathologists and the Korean Society for Cytopathology
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8141973/ https://ncbi.nlm.nih.gov/pubmed/33823566 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4132/jptm.2021.02.22 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|